OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 11:56:14 21/06/2024 am IST | ||
| 19.57 EUR | -0.31% |
|
| Current month | +10.53% | ||
| 1 month | +12.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 19.57 | -0.31% |
| 20/24/20 | 19.63 | +1.87% |
| 19/24/19 | 19.27 | -1.78% |
| 18/24/18 | 19.62 | -2.78% |
| 17/24/17 | 20.18 | -3.31% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 11:56 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC41QD |
| ISIN | DE000HC41QD0 |
| Date issued | 10/02/2023 |
| Strike | 260.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.95 € |
|---|---|
| Lowest since issue | 5.3 € |
| Spread | 0.19 € |
| Spread % | 0.96% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
